Editas Medicine Inc

8EM

Company Profile

  • Business description

    Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

  • Contact

    11 Hurley Street
    CambridgeMA02141
    USA

    T: +1 617 401-9000

    E: [email protected]

    https://www.editasmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,850.0082.40-0.92%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE23,294.75213.42-0.91%
NASDAQ24,429.88101.500.42%
Nikkei 22559,522.52498.240.84%
NZX 50 Index14,237.3526.94-0.19%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,740.3081.50-0.92%
SSE Composite Index3,587.800.03-0.00%

Market Movers